Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus
New hepatitis B virus research reported from Fudan University
April 29th, 2009
"Persistent microbial infections are major public health problems worldwide. Immunotherapies have become an important treatment for persistent infections," investigators in Shanghai, People's Republic of China report. "With the increasing senescent population, low responsiveness to the current preventive vaccines is another challenge for control of infectious diseases. Active immunotherapy by antigen-antibody complexes (IC) is reviewed. IC have shown effects in an hepatitis B surface antigen positive transgenic mouse model by reducing HBsAg, inducing anti-HBs and initiating cytolytic responses. Phase I, IIA and IIB clinical trials in around 300 viral hepatitis B...
Source: Vaccine Weekly (2009-04-29)
|
